ITERUM THERAPEUTICS PUBLIC LIMITED COMPANY

Iterum Therapeutics plc is a Dublin‑based, clinical‑stage pharmaceutical company focused on the development of differentiated anti‑infective medicines to address the growing global threat of multi‑drug‑resistant (MDR) bacteria. Its lead programme, sulopenem, is the first oral and intravenous penem antibiotic that demonstrates a potent spectrum of activity against MDR gram‑negative pathogens in both hospital and community settings. By offering a new oral treatment option, Iterum aims to give physicians and patients a viable alternative to existing therapies for infections that no longer respond to standard antibiotics.

The company’s pipeline is directed at serious, resistant infections that affect millions of people worldwide each year, with a particular emphasis on delivering solutions that can be administered outside the hospital environment. Iterum’s work is supported by a senior management team and board of directors committed to advancing its scientific programme.

As of March 2026, the High Court in Ireland appointed joint liquidators to oversee the winding‑up of Iterum Therapeutics plc and its international subsidiary. Stakeholders with queries are directed to the liquidators’ office. Iterum serves the global medical community, including clinicians, patients and healthcare systems seeking effective, novel oral anti‑infective therapies.